Surf PA leads intense beach rescue

Published Date: 13 Mar 2023

When an elderly boater falls into shallow water, an emergency medical attendant leaves the boat and goes to work.

Read Full News

Latest News

Two Symptoms Linked to Antibiotic Delays in Presumed Sepsis

— GI and respiratory symptoms at presentation both flagged in observational study

Exercise and Cancer Survival; COVID Vaccine and Immune Checkpoint Inhibitors

— Also in TTHealthWatch: colonoscopy after polyp removal

BPAP Intervention Flops in Asthma Study

Goal of decreasing the duration of beta-agonist therapy in the ED showed no significant effect

To Face Scrutiny at ESC: Statins for the Elderly, New Heart Attack Therapies

STAREE trial will give its verdict on primary prevention statins in people ages 70 and up

Radio Silence on Mitch McConnell's Health Persists

84-year-old senator hasn't been seen in public since his hospitalization nearly 3 months ago

Cefepime Tied to Higher Mortality Odds vs Other Beta-Lactams

The danger may be in the dosing, not in the drug itself

Todays Updates

ALOFT-IPF: Admilparant 60 mg Meets Primary FVC End Point

ALOFT-IPF: Admilparant 60 mg Meets Primary FVC End Point

Frontotemporal Dementia Diagnosis, Head Impacts, and Emerging Treatment Approaches Louie Pasculli, Carme Tartaglia, MD

Carmela Tartaglia, MD, FRCPC, discusses the challenges of diagnosing frontotemporal dementia, the evolving role of biomarkers, and emerging approaches to disease modification.

NeurologyLive® Friday 5 — October 9, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 9, 2026.

Personalizing IgA Nephropathy Care Conversations, With Gaia Coppock, MD Gaia Coppock, MD

Why patients with IgA nephropathy want to understand their disease, not just follow instructions.

ABTECT Maintenance Data Show Durable Remission in UC, With Remo Panaccione, MD Remo Panaccione, MD, FRCPC

Phase 3 ABTECT data show ~51% clinical remission and ≥40% endoscopic remission with obefazimod through week 44.

Where Could Obefazimod Fit in UC Treatment, With Remo Panaccione, MD Remo Panaccione, MD, FRCPC

Obefazimod could work as first, second, or third line therapy in ulcerative colitis ahead of a planned FDA submission this year.

Tezepelumab's TSLP Blockade May Address Refractory EoE Gap Arjan Bredenoord, MD

Arjan Bredenoord, MD, details how tezepelumab's selective TSLP inhibition sustained EoE remission through week 52 of the CROSSING trial.

Todays Updates

ALOFT-IPF: Admilparant 60 mg Meets Primary FVC End Point

ALOFT-IPF: Admilparant 60 mg Meets Primary FVC End Point

Frontotemporal Dementia Diagnosis, Head Impacts, and Emerging Treatment Approaches Louie Pasculli, Carme Tartaglia, MD

Carmela Tartaglia, MD, FRCPC, discusses the challenges of diagnosing frontotemporal dementia, the evolving role of biomarkers, and emerging approaches to disease modification.

NeurologyLive® Friday 5 — October 9, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 9, 2026.

Personalizing IgA Nephropathy Care Conversations, With Gaia Coppock, MD Gaia Coppock, MD

Why patients with IgA nephropathy want to understand their disease, not just follow instructions.

ABTECT Maintenance Data Show Durable Remission in UC, With Remo Panaccione, MD Remo Panaccione, MD, FRCPC

Phase 3 ABTECT data show ~51% clinical remission and ≥40% endoscopic remission with obefazimod through week 44.

Where Could Obefazimod Fit in UC Treatment, With Remo Panaccione, MD Remo Panaccione, MD, FRCPC

Obefazimod could work as first, second, or third line therapy in ulcerative colitis ahead of a planned FDA submission this year.

Tezepelumab's TSLP Blockade May Address Refractory EoE Gap Arjan Bredenoord, MD

Arjan Bredenoord, MD, details how tezepelumab's selective TSLP inhibition sustained EoE remission through week 52 of the CROSSING trial.

Latest News

— GI and respiratory symptoms at presentation both flagged in observational study

— Also in TTHealthWatch: colonoscopy after polyp removal

Goal of decreasing the duration of beta-agonist therapy in the ED showed no significant effect

STAREE trial will give its verdict on primary prevention statins in people ages 70 and up

84-year-old senator hasn't been seen in public since his hospitalization nearly 3 months ago

The danger may be in the dosing, not in the drug itself

News All Time

Discordant Tissue Findings in Suspected HLH

Hemophagocytic lymphohistiocytosis is a hyperinflammatory syndrome characterized by an exaggerated immune response to a triggering stimulus.

What Extreme Athletes Teach Us About Sleep Deprivation

What can a 1000-mile race teach MDs about sleep? Dr Alison Kole shares sleep deprivation insights from ultramarathon racing and gives practical tips for exhausted patients.

Omalizumab May Ease Inflammation in Chronic Urticaria

In patients with antihistamine-resistant chronic spontaneous urticaria, omalizumab treatment is linked to clinical improvement and reduced systemic inflammatory markers and D-dimer levels.

Pediatric Lung Transplantation Enters a New Era

New CFTR modulators are reshaping pediatric lung transplantation, forcing clinicians to rethink when children should be referred and listed.

CVS Health's Aetna to Streamline Cancer Treatment Approvals

CVS Health's Aetna health insurance unit will cut back next year on the preapprovals it requires for treatment ⁠for cancer patients to only one medical prior authorization...

Diphtheria Debate Exposes Health Misinformation

A diphtheria death in Sicily has reignited debate over vaccines, migration, and how political spin can distort public health facts.

Azithromycin Use Cuts Cesarean Infections

Azithromycin has been shown to lower the risk for postoperative infection during cesarean deliveries when added to more standard prophylactics such as cefazolin.

Methotrexate for IBD: How Do GIs Use It?

A new study offers the most comprehensive real-world look yet at methotrexate use in treating IBD in everyday practice.

AI Digital Twins Get Better and Better: Cancer in Crosshairs

Digital twins allow doctors to simulate treatment to see what will work best — and the tech has made real strides in cardiology. Oncology remains the bigger challenge.

S1P Modulators: 5 Agents, One Safety Playbook

Five S1P modulators now span neurology and GI. Bruce Cree, MD, PhD, and others weigh in on why selectivity differences are no longer academic.

As-Needed Allergic Rhinitis Meds Comparable to Daily Use

Patients with allergic rhinitis who use medication as needed can achieve symptom control and treatment satisfaction comparable to those achieved by patients who use them daily.

Host-Directed Therapies and Phages in Lung Care

Host-directed and phage therapies are emerging as alternatives to antibiotics in managing lung infections in a worsening antimicrobial resistance crisis.

Mild Brain Injury Frequently Missed in the ED

Only 21% of adults with closed head injury have mTBI diagnosed or clinically suspected in the ED, despite 41% meeting diagnostic criteria, with missed diagnoses most common among middle-aged adults.

D10 Matches D50 for Hypoglycemia, Shows Lower Rebound Risk

A lower-concentration dextrose solution matches the standard treatment for hypoglycemia in the emergency department but carries a lower risk for rebound hypoglycemia.

A Rare Hearing Implant Bypasses Damaged Nerves

When cochlear implants failed, doctors turned to a brainstem auditory implant to restore sound awareness in a patient with profound deafness.

Two-Midnight Rule: Key Strategies for Observation Patients

The Two-Midnight Rule has created important clinical and operational strategies for hospitals.

Recommended News For You

For some patients with bladder cancer that has invaded the muscle, trimodality therapy is just as effective as radical cystectomy.

SBRT Misses the Mark in Prostate Cancer Trial

Isatuximab Boosts MRD Negativity in Multiple Myeloma

Lymph node transfer reduces arm swelling after breast cancer surgery, study shows

Genetics and therapy type determine second cancer risk after childhood treatment, study finds

Combination treatment may help cut lifelong ibrutinib for chronic lymphocytic leukemia patients

Where Did This Very Painful Gluteal Mass Come From?

Recommended Articles For You

Essential Developments in Oncology for Healthcare Excellence 

Uncovering New Hope for Follicular Lymphoma Patients 

Tumor Neighborhoods and Therapy Response: Clinical and Mechanistic Insights 

Exposure Modeling for Bispecific Antibodies: Scientific Foundations and Clinical Implications 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Biomarker panel offers hope for early pancreatic cancer detection

2.

Patients With Melanoma Brain Mets May Fare Better With RT Before Immunotherapy

3.

Dostarlimab Boosts Long-Term Survival in Endometrial Cancer

4.

Healthcare AI, Meant to Save Money, Turns Out to Require a Lot of Expensive Humans

5.

Even when they are not paying attention, children are still learning.

1.

Unlocking the Potential of Leukemia Treatment: A New Hope for Patients

2.

RNA Immunotherapy for Solid Tumors: Mechanisms, Advances, and Clinical Implications

3.

Protein Degradation in Cancer: PROTACs and Targeted Degraders for Previously Difficult-to-Drug Targets

4.

The importance of understanding normal serum osmolality

5.

Demystifying the Mentzer Index: Understanding Its Importance in Inventory Management 

1.

International Conference on Oncology, Cardiology and Critical Care Policy

2.

International Conference on Innovations in Critical Care for Oncology and Cardiology

3.

International Conference on Oncology, Cancer Prevention and Public Health

4.

International Conference on Cancer Nursing and Rehabilitation Strategies

5.

International Conference on Cancer Nursing and Hematology Support

1.

Understanding Risk Factors Associated With Common Cancers

2.

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part IV

3.

Early Warning Signs of Cancer

4.

Thromboprophylaxis In Medical Settings- An Update

5.

Influence of CDK4/6 Inhibitors in Extending Progression-Free Survival (PFS) and Overall Survival in HR+/HER2- mBC Patients

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot